SpyGlass Pharma, Inc.
SGPDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Bimatoprost Implant System
Cataract
Timolol Maleate Ophthalmic Solution, 0.5%
Cataract
Bimatoprost Implant System (High Dose)
Cataract
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Bimatoprost Implant System | Phase 3 | Cataract | - | - |
Timolol Maleate Ophthalmic Solution, 0.5% | Phase 3 | Cataract | - | - |
Bimatoprost Implant System (High Dose) | Phase 2 | Cataract | - | - |
Frequently asked questions
What is in SpyGlass Pharma, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in SpyGlass Pharma, Inc.'s (SGP) pipeline across Phase 3, Phase 2. Its lead program is Bimatoprost Implant System (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is SpyGlass Pharma, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for SpyGlass Pharma, Inc. (SGP) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track SGP biotech catalysts?→
Add SGP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow SpyGlass Pharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.